Acrivon therapeutics to present at the h.c. wainwright bioconnect investor conference

Watertown, mass., april 25, 2023 (globe newswire) -- acrivon therapeutics, inc. (“acrivon” or “acrivon therapeutics”) (nasdaq: acrv), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, today announced the company's chief executive officer and president, peter blume-jensen, m.d., ph.d., will participate in a fireside chat on tuesday, may 2, 2023 at 3:00 p.m. et at the h.c. wainwright bioconnect investor conference in new york.
ACRV Ratings Summary
ACRV Quant Ranking